Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Via News Knowledge File

Chevron Corporation

organization80% conf.·synced Oct 14, 2026

Integrated energy company with upstream and downstream operations globally, stock ticker CVX

60
sourced metrics
611
relationships
20
stated objectives
2
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Return Ytd
39.7%
Oct 13, 2026reference only
Price 52 Week High
217.77USD
Oct 13, 2026reference only
Stock Price
217.73USD
Oct 13, 2026reference only
Market Cap
430184679488USD
Oct 13, 2026reference only
Price 52 Week Low
146.75USD
Oct 13, 2026reference only
Revenue
70055000000.0USD
Jun 30, 2026reference only
Eps
6.11USD_per_share
Jun 30, 2026reference only
Shares Outstanding
1975771274.0shares
Jun 30, 2026reference only
Total Assets
330135000000.0USD
Jun 30, 2026reference only
Net Income
12072000000.0USD
Jun 30, 2026reference only
Cost Of Revenue
36607000000.0USD
Jun 30, 2026reference only
Total Liabilities
134577000000.0USD
Jun 30, 2026reference only
Stockholders Equity
189883000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
2514000000.0USD
Mar 31, 2026reference only
Rd Expense
427000000.0USD
Dec 31, 2025reference only

Stated objectives

Achieve $3-4 billion cost reduction in 2026

source
target: $3-4 billion stated

Offshore production increase of approximately 200,000 bbl/day in 2026

source
target: ~200,000 bbl/day stated

Target doubled shale/tight recovery through stimulation program

source
target: 2x recovery stated

Return cash to shareholders through dividends and buybacks

source
target: $6B per quarter stated

Complete Hess acquisition integration and unlock synergies

source
stated

Maintain record production levels above 4M BOE/day

source
target: 4.086M BOE/day stated

Achieve structural cost reductions of $3-4B

source
target: 3-4 billion USD by 2026-12-31 00:00:00stated

Achieve $1B run-rate synergies from Hess acquisition

source
target: 1 billion USD by 2025-12-31 00:00:00stated

Reach 1M BOE/day production in Permian Basin

source
target: 1000000 BOE per day by 2025-12-31 00:00:00stated

Chevron plateau production target in the Bakken

source
target: 200,000 barrels oil equivalent per day stated

Relationship graph · 611 connections

operates in
85
located in
77
Competes with
68
Covered by
54
Employs
52
acquired by
39
Owns
34
Invested in
29

Via News coverage

Four Major Acquisitions Signal M&A Acceleration Across Food, Tech, and Energy Sectors
March 3, 2026
Canadian Natural Resources' Kirby SAGD Expansion Signals Long-Term Capital Commitment to Thermal Oil Growth
February 18, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com